Bilateral hearing loss during vincristine therapy: A case report

dc.authoridKAYA, Emin/0000-0001-8605-8497;
dc.authorwosidKAYA, Emin/W-2951-2017
dc.authorwosidKALCIOGLU, Mahmut Tayyar/I-5884-2013
dc.authorwosidKalcioglu, M. Tayyar/JAC-1515-2023
dc.contributor.authorKalcioglu, MT
dc.contributor.authorKuku, I
dc.contributor.authorKaya, E
dc.contributor.authorOncel, S
dc.contributor.authorAydogdu, I
dc.date.accessioned2024-08-04T20:13:20Z
dc.date.available2024-08-04T20:13:20Z
dc.date.issued2003
dc.departmentİnönü Üniversitesien_US
dc.description.abstractVincristine sulfate is a chemotherapeutic agent used in different cancer therapies. It is also the first choice of treatment for peripheral T-cell lymphoma with cyclophosphamide and adriamycin. Sudden hearing loss during vincristine therapy is a very rare event. This is a case of a 16-year old girl who developed sudden bilateral hearing loss related to vincristine therapy.en_US
dc.identifier.doi10.1179/joc.2003.15.3.290
dc.identifier.endpage292en_US
dc.identifier.issn1120-009X
dc.identifier.issue3en_US
dc.identifier.pmid12868558en_US
dc.identifier.scopus2-s2.0-0038345540en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage290en_US
dc.identifier.urihttps://doi.org/10.1179/joc.2003.15.3.290
dc.identifier.urihttps://hdl.handle.net/11616/93553
dc.identifier.volume15en_US
dc.identifier.wosWOS:000184062100014en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherE I F T Srlen_US
dc.relation.ispartofJournal of Chemotherapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectvincristineen_US
dc.subjecthearing lossen_US
dc.subjecttoxicityen_US
dc.subjectperipheral T-cell lymphomaen_US
dc.titleBilateral hearing loss during vincristine therapy: A case reporten_US
dc.typeArticleen_US

Dosyalar